Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
These short sellers have bitten off more than they can chew; they are aloof of the science, the data is stunning and speaks for itself. Besides that, they are literal sociopaths. Their sophistry, obfuscation, outright lies and trolling reflect the most primitive, carnal humanity
One of the items that Dr. Scarlett recently discussed is that during the rolling fast track accelerated approval process, they are also looking at additional launches- IND / combos that they hope will be implemented quickly after the first Geron AA. Roches' drug Herceptin has toxicities that develop within a year of use against breast cancer. Data from Roche studies already implemented and proven show that when combined with imetelstat as a front line telomerase inhibitor, Herceptin kills the cancer cells in a fraction of the time minimizing the possible side effects of Herceptin such as heart attacks. (Currently many of these cancer medications are only allowed for a year or less administration due to the side effects and also the tremendous insurance company costs). There are now three main drug companies that need Geron's platform cancer drug desperately over several indications. J&J (Janssen), Incyte, Celgene, and now Merck plus Abbvie and Genentech are watching closely with ready to go imetelstat combo drugs. Now Janssen has confirmed imetelstat’s superior results, (that in effect make Incyte’s and Celgene’s drugs obsolete). Additional companies that also need Imetelstat in their stable are, but not limited to Merck, Abbvie and Genentech. Ask President Jimmy Carter how he feels about the Keytruda-Imetelstat combo research. Also ask about the Imetelstat combo research with ABT-199. We have also seen another slip of the tongue- see the meeting transcript re Genentechs’ drug.
We are only 3 days away from the our gold mine GERN 3rd quarter and Johnson and Johnson loves GERN!!!
Add GERN's drug has FDA fast track and orphan drug status plus
Johnson and Johnson the most conservative pharmaceutical in the world loves GERN.
JNJ has 2 deals with GERN.
JNJ top cancer scientists will be presenting GERN'S drug by invitation to all of Europe June 15.
GERN drug is called transformational to medicine by Johnson and Johnson.
Johnson and Johnson brag that GERN'S drug is 1 of JNJ top future money makers.
The Mayo Clinic calls GERN'S drug tantamount to a cure and the only drug that returns bone marrow to normal.
Geron's President calls GERN'S drug bigger then all of us.
GERN'S drug has been shown to work on 90% of all 2,000 known cancers.
GERN'S drug technology won the Nobel Prize in medicine.
Just GERN'S cash is worth about $ 1 a share.
GERN also has deals with AST / BTX with royalties.
Geron also has deals with Sienna and GERN is the largest share holder of Sienna.
GERN has over 200 telomerase patents and Geron's President says you can't even say telomerase without going through Geron. GERN'S patents are good until 2033.
Geron’s blood cancer patients are living much longer then anyone thought possible.
GERN has over $1Billion in tax credits.
PCYC GERN'S is very similar to GERN only GERN'S technology is 1,000 better. PCYC was bought out by ABBVIE for $262 a share after Johnson and Johnson bid $220 a share. Maybe GERN will sell for $262 a share. Maybe GERN will sell for $100 a share but it is all good.
GERN gets $1 billion in milestone payments from 2 Johnson and Johnson deals.
GERN'S drugs works great in comb with other cancer drugs.
Listen to GERN'S President at the annual share holders meeting 46 minutes into to conference call. All very positive.
GERN'S second Johnson and Johnson deal here.
Johnson & Johnson’s ($JNJ) Janssen Pharmaceuticals has added to an existing partnership with the long-beleaguered Geron ($GERN). The new deal is for exclusive, worldwide rights to the biotech’s oligonucleotide backbone chemistry, as well as novel amidates for ribonucleic acid interference, or RNAi, to prevent, treat or diagnose any disease
The partnership specifically excludes approaches to blood or bone marrow originating cancers as well as any product that works primarily via telomerase inhibition; but these are already covered under an existing deal between the pair that dates back to November 2014.
In addition, Janssen gains a non-exclusive worldwide license to monomer synthesis technology; monomers are the building blocks of oligonucleotides and this is slated to be used as part of the imetelstat program already licensed under the 2014 deal. Imetelstat is a modified short oligonucleotide.
June 17 GERN update here.
The key issue here is that this forthcoming MDS presentation should include a meaty update regarding imetelstat's progress in the expanded subset of patients who are naive to lenalidomide and hypomethylating treatment and lack the del(5q) mutation. And as this is an oral presentation and not simply a poster, these data are probably going to be impressive. Oral conference presentations, after all, are typically reserved for substantial developments.
Now they are calling telomeras the key to aging and GERN's president says you can not even say telomeras without going through GERN!!!
Almost all information is here , 54 pages...
https://www.webcaster4.com/Player/Material?uid=1774543&materialGuid=2b99f443-7112-4a41-b5df-dcbbf1304456
Also : https://pubmedhh.nlm.nih.gov/cgi-bin/abstract.cgi?outid=2967&id=29759988&from=cqsrtbld/0
Imetelstat, Telomerase Inhibitor Myelofibrosis Intravenous drug given every 3-4 weeks
Description: John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Imetelstat, Telomerase Inhibitor Myelofibrosis Intravenous drug given every 3-4 weeks at Imedex Great Debates 2018.
posted on: 4/19/18
Janssen does not permit anyone to talk about reversal of fibrosis when they give presentations. Dr Mascarenhas comment of OS is the topic of the MF CT.
http://www.oncologytube.com/video/imetelstat-telomerase-inhibitor-myelofibrosis-intravenous-drug-given-every-3-4-weeks/10003699
Read below, this is GERN!!!
Johnson and Johnson the most conservative pharmaceutical in the world loves GERN.
JNJ has 2 deals with GERN.
JNJ top cancer scientists will be presenting GERN'S drug by invitation to all of Europe June 15.
GERN drug is called transformational to medicine by Johnson and Johnson.
Johnson and Johnson brag that GERN'S drug is 1 of JNJ top future money makers.
The Mayo Clinic calls GERN'S drug tantamount to a cure and the only drug that returns bone marrow to normal.
Geron's President calls GERN'S drug bigger then all of us.
GERN'S drug has been shown to work on 90% of all 2,000 known cancers.
GERN'S drug technology won the Nobel Prize in medicine.
Just GERN'S cash is worth about $ 1 a share.
GERN also has deals with AST / BTX with royalties.
Geron also has deals with Sienna and GERN is the largest share holder of Sienna.
GERN has over 200 telomerase patents and Geron's President says you can't even say telomerase without going through Geron. GERN'S patents are good until 2033.
Geron’s blood cancer patients are living much longer then anyone thought possible.
GERN has over $1Billion in tax credits.
PCYC GERN'S is very similar to GERN only GERN'S technology is 1,000 better. PCYC was bought out by ABBVIE for $262 a share after Johnson and Johnson bid $220 a share. Maybe GERN will sell for $262 a share. Maybe GERN will sell for $100 a share but it is all good.
GERN gets $1 billion in milestone payments from 2 Johnson and Johnson deals.
GERN'S drugs works great in comb with other cancer drugs.
Listen to GERN'S President at the annual share holders meeting 46 minutes into to conference call. All very positive.
GERN'S second Johnson and Johnson deal here.
Johnson & Johnson’s ($JNJ) Janssen Pharmaceuticals has added to an existing partnership with the long-beleaguered Geron ($GERN). The new deal is for exclusive, worldwide rights to the biotech’s oligonucleotide backbone chemistry, as well as novel amidates for ribonucleic acid interference, or RNAi, to prevent, treat or diagnose any disease
The partnership specifically excludes approaches to blood or bone marrow originating cancers as well as any product that works primarily via telomerase inhibition; but these are already covered under an existing deal between the pair that dates back to November 2014.
In addition, Janssen gains a non-exclusive worldwide license to monomer synthesis technology; monomers are the building blocks of oligonucleotides and this is slated to be used as part of the imetelstat program already licensed under the 2014 deal. Imetelstat is a modified short oligonucleotide.
June 17 GERN update here.
The key issue here is that this forthcoming MDS presentation should include a meaty update regarding imetelstat's progress in the expanded subset of patients who are naive to lenalidomide and hypomethylating treatment and lack the del(5q) mutation. And as this is an oral presentation and not simply a poster, these data are probably going to be impressive. Oral conference presentations, after all, are typically reserved for substantial developments.
Now they are saying that telomerase is the key to aging and GERN owns all the telomerase patents too.
DUMP - your negative opinion is = 0 , empty words .... Thousands will create generational wealth from holding this stock. The science is good. People are alive 2 plus years longer than they should be because of Imetelstat. That story is bigger than all of us and will play out over the next year. IMO all recent indicators from JNJ have also been favorable. Now, I can't change the personal mute choices of others or mysteriously appear from nowhere to dominate the Top Reactions page like you and other shorts living on borrowed time. But I have done a tremendous amount of my own due diligence. Good enough for me.
I have some last word for you: who laughs last, laughs best. I hope not to many readers fall for your BS ...
Geron Announces Oral Presentation at the 23rd Congress of the European Hematology Association (EHA) to be held in Stockholm, Sweden from June 14-17, 2018. about GERON . On November 13, 2014, Geron entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., to develop and commercialize imetelstat for oncology, including hematologic myeloid malignancies, and all other human therapeutics uses. Under the terms of the agreement, Geron received an upfront payment of $35 million and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. All regulatory, development, manufacturing and promotional activities related to imetelstat are being managed through a joint governance structure, with Janssen responsible for these activities.
http://markets.on.nytimes.com/research/stocks/news/press_release.asp?docTag=201805170905PRIMZONEFULLFEED7269216&feedID=600&press_symbol=137328
Imetelstat, Telomerase Inhibitor Myelofibrosis Intravenous drug given every 3-4 weeks
Description: John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Imetelstat, Telomerase Inhibitor Myelofibrosis Intravenous drug given every 3-4 weeks at Imedex Great Debates 2018.
posted on: 4/19/18
Janssen does not permit anyone to talk about reversal of fibrosis when they give presentations. Dr Mascarenhas comment of OS is the topic of the MF CT.
http://www.oncologytube.com/video/imetelstat-telomerase-inhibitor-myelofibrosis-intravenous-drug-given-every-3-4-weeks/10003699
Imetelstat, Telomerase Inhibitor Myelofibrosis Intravenous drug given every 3-4 weeks
Description: John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Imetelstat, Telomerase Inhibitor Myelofibrosis Intravenous drug given every 3-4 weeks at Imedex Great Debates 2018.
posted on: 4/19/18
Janssen does not permit anyone to talk about reversal of fibrosis when they give presentations. Dr Mascarenhas comment of OS is the topic of the MF CT.
http://www.oncologytube.com/video/imetelstat-telomerase-inhibitor-myelofibrosis-intravenous-drug-given-every-3-4-weeks/10003699
Less
Thousands will create generational wealth from holding this stock. The science is good. People are alive 2 plus years longer than they should be because of Imetelstat. That story is bigger than all of us and will play out over the next year. IMO all recent indicators from JNJ have also been favorable. Now, I can't change the personal mute choices of others or mysteriously appear from nowhere to dominate the Top Reactions page like @xx and other shorts living on borrowed time. But I have done a tremendous amount of my own due diligence. Good enough for me.
Jun 3rd, 2018 .
Geron logoArnhold LLC acquired a new stake in Geron Co. (NASDAQ:GERN) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 154,700 shares of the biopharmaceutical company’s stock, valued at approximately $657,000. Arnhold LLC owned approximately 0.10% of Geron at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. OMERS ADMINISTRATION Corp bought a new stake in shares of Geron during the 1st quarter valued at $442,000. Swiss National Bank lifted its position in shares of Geron by 13.1% during the 1st quarter. Swiss National Bank now owns 284,400 shares of the biopharmaceutical company’s stock valued at $1,209,000 after acquiring an additional 32,900 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in shares of Geron during the 1st quarter valued at $106,000. Wells Fargo & Company MN lifted its position in shares of Geron by 17.0% during the 1st quarter. Wells Fargo & Company MN now owns 124,353 shares of the biopharmaceutical company’s stock valued at $529,000 after acquiring an additional 18,111 shares during the period. Finally, MetLife Investment Advisors LLC bought a new stake in shares of Geron during the 4th quarter valued at $136,000. 34.46% of the stock is currently owned by hedge funds and other institutional investors.
https://stocknewstimes.com/2018/06/03/arnhold-llc-takes-position-in-geron-co-gern.html
U.S. National Library of Medicine
•Title: Transient Telomerase Inhibition with Imetelstat Impacts DNA Damage Signals and Cell Cycle Kinetics.
Author: Thompson CA, Gu A, Yang S, Mathew V, Fleisig HB, Wong JM.
Journal: Mol Cancer Res; 2018 May 14; ():. PubMed ID: 29759988.
https://pubmedhh.nlm.nih.gov/cgi-bin/abstract.cgi?outid=2967&id=29759988&from=cqsrtbld/0
Major upcoming catalysts can make Geron (GERN) stock soar
This blog post is for my followers in advance of an upcoming article submission here on Seeking Alpha.
Geron has major upcoming catalysts, I list them below with my price targets:
- EHAC '18 Late Breaking Abstracts Available Online (June 1) - $6
- European Hematology Association Congress (June 14-17) - $8
- Accelerated Approval In Myelofibrosis (July 31) $16
- Continuation Decision by Johnson and Johnson (JNJ) (August 31) $20
- Accelerated Approval in Myelodysplastic Syndrome (September 30) $30
https://seekingalpha.com/instablog/3163201-medtechbio/5164810-upcoming-catalysts-can-launch-geron-15-per-share
This is just the complete Right way to look at it.....
Janssen is not about to divorce Geron. Rather, when asked during Johnson & Johnson's Q1 2018 earnings CC by Geoff Meacham as to its strategy around its pipeline and acquisitions, Johnson & Johnson's EVP and CFO Caruso assured Meacham that its pipeline was strong. In this regard he specifically referenced eight new drug applications for products having billion-dollar potential planned by 2021.
Caruso's response ties in directly with Johnson & Johnson's Q1 2018 pipeline slide - The First one listed is IMETELSTAL for Myelofibrosis.
Caruso's response references eight drugs set for filing. Johnson & Johnson's 4/18/18 slide references eight planned NME filings by 2021. The first one listed is imetelstat for Myelofibrosis. I take this as meaning that Johnson & Johnson has specific intent of following through on expectations around issuing its continuation decision.
p.s. Nice try Dump , your short position is $5.00 ..... Target Geron to hit $10 by 10/10........
Read this one. It says 'No further shares of common stock can be issued under the Sales Agreement'
https://www.nasdaq.com/press-release/geron-corporation-reports-first-quarter-2018-financial-results-20180510-01259
The fact that 5 Janssen representatives will be presenting at next month's conference for imetelstat. That's kind of a tell that the shorts are Wrong imo
How Dirty this people from SA .... My email to SA writer! https://ibb.co/nisf38
TRUTH, This news is manipulated. Its a stock incentive for employees. Its not a public offering or filing for such a future offer. Go to company website and read the SEC filing.
GOT A QUESTION FOR SHORTIES
r u feeling any stress today? a little STRESS? or a lot of STRESSSSSSSS????
Early strategic licenses and acquisitions
•
apalutamide (ARN-509)
•
erdafitinib (FGFR inhibitor)
•
JNJ-9375 (anti-thrombin)
•
pimodivir (JNJ-3872)
•
JNJ-4178 (3DAA)
•
imetelstat
•
niraparib
•
JNJ-5111 (HM12525A)
•
JNJ-2463 (CB1 inverse agonist)
•
JNJ-7107 (CD40 agonist)
•
talacotuzumab (CSL362)
•
duvortuximab (MGD011)
•
JNJ-1860 (ExPEC vaccine)
•
JNJ-7957 (BCMA x CD3)
•
lumicitabine (JNJ-1575)
Our Pipeline Evolution
10 NME filings 2015-2019, each with $1B+ potential
sirukumab Rheumatoid arthritis
fulranumab Osteoarthritic pain
daratumumab Multiple myeloma
esketamine Treatment resistant depression
guselkumab Psoriasis
apalutamide
(ARN-509) Pre-metastatic prostate cancer
lumicitabine
(JNJ-1575) RSV infections
erdafitinib
(FGFR inhibitor) Solid tumors
imetelstat Myelofibrosis
AL-335 HCV
Our Pipeline Evolution
JNJ-7922
http://files.shareholder.com/downloads/JNJ/0x0x943362/5ED20A6F-9534-4698-81E8-80A78BDD0285/William_Hait_Slides.pdf
Plus - INSTITUTIONS shares HELD : Fidelity Management and Research Company 19,739,475 shares
http://investors.morningstar.com/ownership/shareholders-major.html?t=GERN
Fidelity® Select Biotechnology 15,165,701 9.44 0 0 0.75 03/31/2018
http://investors.morningstar.com/ownership/shareholders-major.html?t=GERN
Click on Fidelity® Select Biotechnology - you will get this : http://www.morningstar.com/funds/XNAS/FBIOX/quote.html
FBIOX by Fidelity, Holds 15 million shares of GERN. Ask your FA why they're holding so many shares?
Median OS is more than 23 months. A specified number of deaths have been reached in the study and this allowed JNJ to project median OS. It looks like IMbark data is good enough to trigger continuation. Chance of affirmative continuation is 98%. 2% chance of negative decision and this is a better scenario than an affirmative decision. Why? Because the data is superb.
Listen the the conference call starting at 46 minutes into the call. Janssen needs GERN a lot more then GERN needs Janssen. GERN would love to get their imetelstat drug rights back and go it alone. We have a winning drug here. And now the world knows
That's Right !!! You said- (great ill buy in the 4th quarter 6 months from now ) You will , but the price can be 0.50-0.60c. .... P.S. NOW YOU EAMPTY WORDS TIME LOSER WITH YOUR CREW...
never, said , never.......
Hard to ignore significant growth in revenue with more than 100% growth for Q1 ‘18 and projecting more than 100% for full year growth.
Look tree Time losers brothers out ...... ,, DOGS BARKING , BUT CARAVAN GOES ,,
Fluticare is not yet up to expectations and they still did 4.5 mil in sales? Wow, wait tell they sort out the Rx issue and Fluticare gets its footing!
Honeycomb777 , TrueTrades - Unhappy two brothers out , your Negativity will bring in your life even more Negativity .... , but your opinions now is = 0 !!!
GERON is listed on CG Capital page, under "Clients:"
http://cg.capital/#our-clients
DUMP , what are you talking about ???
(Your track record is trash, bud:)
THIS MY TRACK RECORD :
Delcatch - profit $7620.Jan 2 2018, when stock jump
INNV - profit $37K July 2016 when stock jump 0.66 c. reloaded last December and hold now 206K shares
Cord Blood Blood America profit $27K
NOK - $136K profit when stock jump over night September 3 2013 . (Microsoft deal )
AMD - sold early , but profit $21K..
p.s. GERN - before long position was 20K shares - sold 10K March ,profit $29K , NOW hold 10K for Very Long ...
Enjoy your weekend .
I see the wisdom in Scarlett's statement and am astonished that so many are missing the point. GERN is no beholden to JnJ for its survival, it is perfectly capable of standing on its own. That is both a shot across the bow of JnJ not to try an lowball and a signal to other possible suitors that GERN has independent value.
Stop worrying about what the price is today or next week, watch Scarlett set this puppy up to maximize the sale price. After-all, that is what he does best.
LIAR....... GERON The safety profile is reviewed by the FDA and given a continuation after careful review of the circumstance. It granted Fast Track Designation. NICE TRY .....
ABBVIE wants GERN. ABBVIE is already using GERN'S drug in AML. ABBVIE paid $262 a share to steal PCYC, GERN'S sister company away from Johnson and Johnson only GERN'S technology is 1,000 times better then PCYC's and GERN'S technology won the Nobel Prize
Think about it! J&J would have dropped GERN like a hot Cow pie if they had any early indication Imet was a loser drug!
I believe J&J is all in and will deliver us Longs goods news of an Opt-in and royalty payment in September! Oh yeah, don't forget, J&J filed for a global patent last August because they felt like it!!! (08-02-2018) - Janssen BioTech applies for global patent for combo treatment for hematologic cancers, includes imetelstat.
There are now at 3 main drug companies that need Geron's cancer drug desperately over several indications. J&J (Janssen), Incyte, Celgene, and now Merck plus Abbvie are watching closely with possible combo drugs. Now that the company has confirmed imetelstat’s superior results, (that in effect make Incyte’s and Celgene’s drugs obsolete. Additional companies that need Imetelstat in their stable are, but not limited to Merck and Abbvie. Ask President Jimmy Carter how he feels about the Keytruda-Imetelstat combo research. Also ask about the Imetelstat combo research with ABT-199.
All Systems Go! For Geron And JNJ In Both iMerge And iMbark Trials For MF And MDS
May 10, 2018 6:30 PM ET
•Median Overall Survival Keeps Growing In Unprecedented 23+ Months In The Myelofibrosis iMbark Trial.
•iMerge Part 1 Expansion Phase is now beyond critical 8 Week point for transfusion independence.
•Shorts run out of supply for stocks to cover as 2015 ATM program is now complete; shares available will now dry up very quickly.
https://seekingalpha.com/instablog/3163201-medtechbio/5157556-systems-go-geron-jnj-imerge-imbark-trials-mf-mds